Last reviewed · How we verify

NCT02474888: MONITUX

Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis

Terminated Last updated 16 November 2020
What this trial tests

trial testing blood specimen in Granulomatosis, Wegener's in 28 participants. Terminated before completion.

Timeline
15 September 2015
Primary endpoint
12 June 2020
12 June 2020

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Saint Etienne
StatusTerminated
Study typeOBSERVATIONAL
Enrollment28
Start date15 September 2015
Primary completion12 June 2020
Estimated completion12 June 2020
Sites4 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Who can join

18 and older, any sex, with Granulomatosis, Wegener's or Microscopic Polyangiitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the investigators' study is to evaluate whether monitoring serum rituximab levels could be an interesting tool in the follow-up of ANCA-associated vasculitis patients. All consecutive patients, hospitalized for a new diagnosis of ANCA-associated vasculitis or the relapse of a known ANCA-associated vasculitis, in which the decision to start an induction regimen with rituximab has been taken, will be included. Serum rituximab levels (along with serum anti-rituximab antibodies levels) will be determined (at M+1 and M+3) and the correlation with clinical outcome at M+6 will be analyzed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of blood specimen

Trials testing the same drug.

Other Centre Hospitalier Universitaire de Saint Etienne trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02474888.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing